Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mika Kitahora"'
Autor:
Hironori Fujii, Yukino Ueda, Chiemi Hirose, Koichi Ohata, Kumiko Sekiya, Mika Kitahora, Shiori Sadaka, Senri Yamamoto, Daichi Watanabe, Hiroko Kato-Hayashi, Hirotoshi Iihara, Ryo Kobayashi, Miho Kaburaki, Nobuhisa Matsuhashi, Takao Takahashi, Akitaka Makiyama, Kazuhiro Yoshida, Hideki Hayashi, Akio Suzuki
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract Background The effect of pharmaceutical intervention to treat adverse events on quality of life (QOL) in outpatients receiving cancer chemotherapy is unclear. We investigated whether pharmaceutical intervention provided by pharmacists in col
Externí odkaz:
https://doaj.org/article/3e27ad5d37c74e7f8a5a46f83069ed5b
Autor:
Kazuhiro Yoshida, Akitaka Makiyama, Miho Kaburaki, Senri Yamamoto, Nobuhisa Matsuhashi, Takao Takahashi, Hirotoshi Iihara, Yukino Ueda, Kumiko Sekiya, Daichi Watanabe, Shiori Sadaka, Koichi Ohata, Chiemi Hirose, Hideki Hayashi, Ryo Kobayashi, Hironori Fujii, Akio Suzuki, Mika Kitahora, Hiroko Kato-Hayashi
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences. 8
Background The effect of pharmaceutical intervention to treat adverse events on quality of life (QOL) in outpatients receiving cancer chemotherapy is unclear. We investigated whether pharmaceutical intervention provided by pharmacists in collaboratio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbb9155eb8ddf07d95c675f213a8d9e9
https://doi.org/10.1186/s40780-022-00239-w
https://doi.org/10.1186/s40780-022-00239-w
Autor:
Hironori Fujii, Akio Suzuki, Takao Takahashi, Kazuhiro Yoshida, Yunami Yamada, Hirotoshi Iihara, Chiemi Hirose, Daichi Watanabe, Takuma Ishihara, Nobuhisa Matsuhashi, Mika Kitahora
Publikováno v:
The Oncologist
Objective TAS‐102 is effective for treating patients with metastatic colorectal cancer (mCRC). This study determined whether combining bevacizumab (Bmab) with TAS‐102 improves clinical outcomes in refractory mCRC. Patients and Methods We retrospe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b32a3d0ddc848f91dab8f130d75d18b
https://doi.org/10.1634/theoncologist.2019-0541
https://doi.org/10.1634/theoncologist.2019-0541
Autor:
Yoshinori Itoh, Yuka Sasaki, Daizo Kaito, Komei Yanase, Natsumi Arai, Hirotoshi Iihara, Yasushi Ohno, Shinya Minatoguchi, Mika Kitahora, Chiemi Hirose, Fumitaka Ito, Sayaka Toyoshi, Norihiko Funaguchi, Junki Endo
Publikováno v:
Anticancer Research. 37:1965-1970
Background Carboplatin (CBDCA) is known to exhibit a high emetic risk among moderate-emetic risk anticancer drugs, and the dose of CBDCA varies in different therapies. In concurrent chemoradiotherapy (CCRT) for non-small cell lung cancer (NSCLC), the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5987a4b93bccd971fa8ac8c978d2cb57
https://doi.org/10.21873/anticanres.11537
https://doi.org/10.21873/anticanres.11537
Autor:
Chiemi Hirose, Takuma Ishihara, Koichi Ohata, Nobuhisa Matsuhashi, Masashi Ishihara, Hirotoshi Iihara, Akio Suzuki, Takao Takahashi, Kumiko Okuda, Kumiko Sekiya, Masayo Naruse, Kazuhiro Yoshida, Hironori Fujii, Tadashi Sugiyama, Minako Nawa-Nishigaki, Hiroko Kato-Hayashi, Mika Kitahora
Publikováno v:
Supportive Care in Cancer
Background Outpatient cancer chemotherapy may lead to improved quality of life (QOL) by allowing treatment to continue without impairing the social lives of patients compared with hospitalization. However, the occurrence of serious adverse events may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccd34bab228dbc914061d5fb9d317775
https://pubmed.ncbi.nlm.nih.gov/32281034
https://pubmed.ncbi.nlm.nih.gov/32281034
Autor:
Hideki Hayashi, Yoshihisa Fukuda, Chiemi Hirose, Junki Endo, Yasushi Ohno, Hirotoshi Iihara, Daizo Kaito, Komei Yanase, Akio Suzuki, Mika Kitahora, Tadashi Sugiyama
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 134
Objectives Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) represent the first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Afatinib is a second-generation EGFR-TKI with excellen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83e7d7d944a1eab87be89a826adcb5ec
https://pubmed.ncbi.nlm.nih.gov/31319966
https://pubmed.ncbi.nlm.nih.gov/31319966
Autor:
Daizo, Kaito, Hirotoshi, Iihara, Norihiko, Funaguchi, Junki, Endo, Fumitaka, Ito, Komei, Yanase, Sayaka, Toyoshi, Yuka, Sasaki, Chiemi, Hirose, Natsumi, Arai, Mika, Kitahora, Yasushi, Ohno, Yoshinori, Itoh, Shinya, Minatoguchi
Publikováno v:
Anticancer research. 37(4)
Carboplatin (CBDCA) is known to exhibit a high emetic risk among moderate-emetic risk anticancer drugs, and the dose of CBDCA varies in different therapies. In concurrent chemoradiotherapy (CCRT) for non-small cell lung cancer (NSCLC), the weekly adm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::519e2f8d4d895987a6e73d0e10df61f1
https://pubmed.ncbi.nlm.nih.gov/28373467
https://pubmed.ncbi.nlm.nih.gov/28373467
Autor:
Hirotoshi Iihara1,2,3 iihara.hirotoshi.p7@f.gifu-u.ac.jp, Mototsugu Shimokawa4,5, Hiroko Bando6, Yoshimi Niwa7, Yutaka Mizuno8, Yoshihiro Kawaguchi9, Mika Kitahora1, Akari Murakami10, Masaaki Kawai11,12, Kazushige Ishida13, Makoto Takeuchi14, Kazuhiro Ishihara15, Tomokazu Iyoda16, Takumi Nakada17, Atsuko Ogiso18, Yasuyuki Kojima19, Fumiyoshi Kumagai20, Aya Sawa21, Ryutaro Mori7, Kosuke Higuchi22
Publikováno v:
Journal of Cancer. 2023, Vol. 14 Issue 14, p2644-2654. 11p.